

CYduct Diagnostics Inc. Completes Audit of its Consolidated Financial Statements

WESTPORT, CT / ACCESSWIRE / October 04, 2022 / CYduct Diagnostics, Inc. (OTC PINK: CYDX), a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness, is pleased to announce that TPS Thayer LLC, an independent audit firm, has completed its audit of the company's consolidated financial statements for the years ended June 30, 2022 and 2021.

"I am incredibly proud of what our team and auditors have accomplished in completing this audit in an efficient manner. This is a major milestone for us, and while we are working hard behind the scenes on our technologies, we also look forward to taking the steps required in becoming a fully reporting entity," said Dominick Gatto, President.

We encourage shareholders to visit our official corporate social media account for updates:

<https://twitter.com/CYductDx>

<https://www.linkedin.com/company/cyductdx/>

<https://www.facebook.com/CYductDiagnostics>

About CYduct Diagnostics, Inc.:

CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products will be available on the Company's website at: www.CYductdx.com

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the Company, are forward-looking statements that involve significant risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The inability to raise additional capital, and technical complications in research, product development and validation, among other things, could prevent the implementation of strategically significant plan(s) outlined above. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

CONTACT:

CYduct Diagnostics, Inc.

Investor Relations +1-888-545-9112

SOURCE: CYduct Diagnostics, Inc